Sanofi, GSK prep regulatory filings for Covid-19 vaccine after posting PhIII, booster data — but who will use it?
Armed with the final cut of Phase III results on their Covid-19 vaccine both as a primary series and a booster, Sanofi and GlaxoSmithKline are finally ready to seek regulatory authorizations.
In two separate trials, the pharma giants said their adjuvanted protein-based vaccine demonstrated “universal ability” to boost neutralizing antibodies whether following mRNA or adenovirus shots, as well as 57.9% efficacy against any symptomatic Covid-19 disease. Protection against moderate or severe disease was better at 75% — and yet higher against severe disease and hospitalizations at 100%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
